Beam Therapeutics Inc Forecast, price target & analysts
Beam Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Beam Therapeutics Inc Classifications & Recommendation:
Beam Therapeutics Inc Price Target
| Target Price | $43.75 |
| Price | $16.88 |
| Potential |
159.18%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Beam Therapeutics Inc 2026 .
The average Beam Therapeutics Inc target price is $43.75.
This is
159.18%
register free of charge
$80.00
373.93%
register free of charge
$20.00
18.48%
register free of charge
|
|
| A rating was issued by 18 analysts: 15 Analysts recommend Beam Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Beam Therapeutics Inc stock has an average upside potential 2026 of
159.18%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 63.52 | 53.56 |
| 83.18% | 15.68% | |
| EBITDA Margin | -619.71% | -852.47% |
| 1,395.95% | 37.56% | |
| Net Margin | -593.10% | -870.93% |
| 1,590.35% | 46.84% |
16 Analysts have issued a sales forecast Beam Therapeutics Inc 2025 . The average Beam Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Beam Therapeutics Inc EBITDA forecast 2025. The average Beam Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Beam Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Beam Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.58 | -4.64 |
| 166.28% | 1.31% | |
| P/E | negative | |
| EV/Sales | 9.20 |
17 Analysts have issued a Beam Therapeutics Inc forecast for earnings per share. The average Beam Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Beam Therapeutics Inc...
Current Beam Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
